StockData
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp (EW) stock

EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.43−1.68 (-1.57%)

Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –

Edwards Lifesciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Edwards Lifesciences's revenue for the twelve months ending Jun 30, 2026 was $6.51B, up 14.6% year over year. For fiscal 2025 it was $6.07B, up 11.5% from the year before. Over ten years it grew 9.3% a year on average. The highest annual figure on record is $6.07B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.07B+11.5%
FY2024Dec 31, 2024$5.44B+8.6%
FY2023Dec 31, 2023$5.01B+12.2%
FY2022Dec 31, 2022$4.46B-14.7%
FY2021Dec 31, 2021$5.23B+19.3%
FY2020Dec 31, 2020$4.39B+0.9%
FY2019Dec 31, 2019$4.35B+16.8%
FY2018Dec 31, 2018$3.72B+8.4%
FY2017Dec 31, 2017$3.44B+15.9%
FY2016Dec 31, 2016$2.96B+18.8%
FY2015Dec 31, 2015$2.49B+7.4%
FY2014Dec 31, 2014$2.32B+13.6%
FY2013Dec 31, 2013$2.05B+7.7%
FY2012Dec 31, 2012$1.90B+13.2%
FY2011Dec 31, 2011$1.68B+16.0%
FY2010Dec 31, 2010$1.45B+9.5%
FY2009Dec 31, 2009$1.32B+6.8%
FY2008Dec 31, 2008$1.24B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.74B+13.6%
Q1 FY2026Mar 31, 2026$1.65B+16.7%
Q4 FY2025Dec 31, 2025$1.57B+13.3%
Q3 FY2025Sep 30, 2025$1.55B+14.7%
Q2 FY2025Jun 30, 2025$1.53B+11.9%
Q1 FY2025Mar 31, 2025$1.41B+6.2%
Q4 FY2024Dec 31, 2024$1.39B+9.4%
Q3 FY2024Sep 30, 2024$1.35B+8.9%
Q2 FY2024Jun 30, 2024$1.37B+7.1%
Q1 FY2024Mar 31, 2024$1.33B+8.9%
Q4 FY2023Dec 31, 2023$1.27B+194.6%
Q3 FY2023Sep 30, 2023$1.24B-5.7%
Q2 FY2023Jun 30, 2023$1.28B-6.9%
Q1 FY2023Mar 31, 2023$1.22B-8.9%
Q4 FY2022Dec 31, 2022$429.90M-67.7%
Q3 FY2022Sep 30, 2022$1.32B+0.7%
Q2 FY2022Jun 30, 2022$1.37B-0.2%
Q1 FY2022Mar 31, 2022$1.34B+10.2%
Q4 FY2021Dec 31, 2021$1.33B+11.6%
Q3 FY2021Sep 30, 2021$1.31B+14.8%
Q2 FY2021Jun 30, 2021$1.38B+48.8%
Q1 FY2021Mar 31, 2021$1.22B+7.8%
Q4 FY2020Dec 31, 2020$1.19B+1.5%
Q3 FY2020Sep 30, 2020$1.14B+4.3%
Q2 FY2020Jun 30, 2020$925.00M-14.9%
Q1 FY2020Mar 31, 2020$1.13B+13.7%
Q4 FY2019Dec 31, 2019$1.17B+20.1%
Q3 FY2019Sep 30, 2019$1.09B+20.7%
Q2 FY2019Jun 30, 2019$1.09B+15.2%
Q1 FY2019Mar 31, 2019$993.00M+11.0%
Q4 FY2018Dec 31, 2018$977.70M+10.0%
Q3 FY2018Sep 30, 2018$906.60M+10.4%
Q2 FY2018Jun 30, 2018$943.70M+12.1%
Q1 FY2018Mar 31, 2018$894.80M+1.3%
Q4 FY2017Dec 31, 2017$888.50M+15.7%
Q3 FY2017Sep 30, 2017$821.50M+11.1%
Q2 FY2017Jun 30, 2017$841.80M–
Q1 FY2017Mar 31, 2017$883.50M–
Q4 FY2016Dec 31, 2016$767.70M–
Q3 FY2016Sep 30, 2016$739.40M–

More Edwards Lifesciences figures

See a number that looks wrong?